Allergen Immunotherapy for Asthma: Guidelines and Real World Applications (AAN)
Price: FREE for members and non-members
Session recorded on July 17, 2023
Speaker: Desiree Larenas Linnemann, MD
Despite augmenting evidence of AIT efficacy and effectiveness in asthma, guidelines still limit its role. Tune in to this webinar to hear an expert in the field discuss results from recent AIT in asthma trials and to learn how to select the correct patient, the correct allergen, and the correct timing for AIT in the treatment of asthma.
Viewers can earn credit by completing the post-test questions.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Allied Health Professionals
Upon completion of this activity learners should be able to:
1. Discuss the place of AIT in asthma guidelines
2. Be acquainted with results from recent AIT in asthma trials, specificly RWE
3. Select the correct patient, correct allergen and correct timing for AIT in asthma
All relevant financial relationships have been mitigated.
The individuals listed below disclose the following financial relationships:
Desiree Larenas Linnemann, MD
Speaker: Bayer, Viatris, Carnot, Abbvie, ALK, Astra Zeneca, Chiesi, GSK, Menarini, Pfizer, Sanofi, Novartis
Grants: Abbvie, Bayer, Lilly, Sanofi, Astra Zeneca, Pfizer, Novartis, Circassia, GSK
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance